Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early Cancers

The six-marker assay serves as an initial component of Nucleixs screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 26, 2020
Information
Tags: 
General Health, Health, Science, Research, Oncology, RTT, Medicine, Clinical medicine, Health, Infectious causes of cancer, Medical tests, Bladder cancer, Cancer, Screening, Molecular diagnostics, Oncology
Geotags: 
United States, Israel, Middle East, California
⚠generated by AI ↴
Summary
Key Points: 
  • The six-marker assay serves as an initial component of Nucleixs screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.
  • We look forward to sharing updates on the promising data supporting our Lung EpiCheck for patients at high risk for lung cancer.
  • We are building an EpiCheck franchise, beginning with our Bladder EpiCheck testing kit marketed in Europe for bladder cancer recurrence.
  • We are advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases.


Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020. The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.

“Monitoring methylation changes in tumors that shed circulating cell-free DNA demonstrates an alternative approach to identifying many cancers, particularly at early stages, with just a handful of markers that are measured using the power of our proprietary EpiCheck technology,” said Chris Hibberd, chief executive officer of Nucleix. “We have already seen success with this platform, having discovered, developed and launched a bladder cancer recurrence test kit in Europe and advanced a new test for patients at high-risk for lung cancer based on encouraging results seen with a disease specific panel. We look forward to sharing updates on the promising data supporting our Lung EpiCheck for patients at high risk for lung cancer.”

Details are as follows:

  • Title: Discovery of a core-panel of markers for a blood-assay for cancer detection utilizing cfDNA methylation changes (#1522)
  • Presenter: Dr. Lasika Seneviratne, SCORA/LA Cancer Network

About Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. We are building an EpiCheck franchise, beginning with our Bladder EpiCheck testing kit marketed in Europe for bladder cancer recurrence. We are advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. For more information, please visit https://www.nucleix.com/.

Copyright: 
Copyright Business Wire 2020